ArticleEpidemiology and infection2025
Analysis of influencing factors of concurrent primary liver cancer in hepatitis B patients and construction of column chart prediction model.
Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A predictive column chart was developed to assess the risk of primary liver cancer (PLC) in hepatitis B patients. Data from 107 PLC patients and 107 controls were used as the training set, with 92 patients as the validation set. An additional 446 patients from other hospitals, including 15 with PLC, formed the external validation group. Multivariate logistic regression identified gender, BMI, alcohol consumption, diabetes, family history of liver cancer, cirrhosis, and HBV DNA load as independent risk factors. The model showed strong discrimination with AUCs of 0.882 and 0.859 in the training and validation sets, respectively, and good calibration (Hosmer-Lemeshow χ² = 2.648, P = 0.954; χ² = 4.117, P = 0.846). Decision curve analysis (DCA) confirmed clinical benefit within a risk threshold of 0.07-0.95. In the external validation group, the model maintained discrimination (AUC = 0.863) and calibration (Hosmer-Lemeshow χ² = 7.999, P = 0.434), with DCA showing net benefit across 0.14-0.95. These results indicate the column chart is a reliable tool for PLC risk prediction in hepatitis B patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.